title: [Long-term therapy with nucleoside analog entecavir (baraclude) in patients with chronic hepatitis B].
abstract: Complications of HBV infection include cirrhosis and hepatocellular carcinoma (HCC), which together cause over 500.000 deaths annually. There are many risk factors of disease progression as: age, sex, comorbidities, family history, HBV genotypes, viral load, HBeAg status, disease stage etc. Chronic hepatitis B patients with high viral load have the highest risk of progressing to these life-threatening complications. The management of chronic hepatitis B currently rests with long-term therapy using nucleoside analogs. The goal of this therapy is sustained HBV DNA suppression, improving quality of life and preventing progression of the disease to cirrhosis, end-stage liver disease, HCC and death. The major limitations of long-term therapy is antiviral resistance. Entecavir provides sustained viral suppression and histological benefit with minimal resistance during long-term treatment of chronic hepatitis B, it is well-tolerable and has good safety profile, simple dosing and simple monitoring requirements.
authors.affiliation: Katedra Chorób Zakaźnych i Hepatologii Collegium Medicum im. L. Rydygiera w Bydgoszczy Uniwersytet Mikolaja Kopernika w Toruniu. kikchzak@cm.umk.pl
authors.forename: Małgorzata
authors.initials: M
authors.lastname: Pawłowska
authors.forename: Waldemar
authors.initials: W
authors.lastname: Halota
mesh_terms: D000998:Antiviral Agents / Q000494:pharmacology / Q000627:therapeutic use*; D018450:Disease Progression; D005260:Female; D006147:Guanine / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000627:therapeutic use; D006515:Hepatitis B virus / Q000187:drug effects; D019694:Hepatitis B, Chronic / Q000188:drug therapy* / Q000503:physiopathology; D006801:Humans; D008137:Longitudinal Studies; D008297:Male; D016032:Randomized Controlled Trials as Topic; D016896:Treatment Outcome
chemical_list: D000998:Antiviral Agents; C413685:entecavir; D006147:Guanine